Cargando…
LunX-CAR T Cells as a Targeted Therapy for Non-Small Cell Lung Cancer
Non-small cell lung cancer (NSCLC) carries a high mortality, and efficacious therapy is lacking. Therapy using chimeric antigen receptor (CAR) T cells has been used efficaciously against hematologic malignancies, but the curative effect against solid tumors is not satisfactory. A lack of antigen tar...
Autores principales: | Hu, Ziming, Zheng, Xiaohu, Jiao, Defeng, Zhou, Yonggang, Sun, Rui, Wang, Baolong, Tian, Zhigang, Wei, Haiming |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7210386/ https://www.ncbi.nlm.nih.gov/pubmed/32405534 http://dx.doi.org/10.1016/j.omto.2020.04.008 |
Ejemplares similares
-
Immunogenic senescence sensitizes lung cancer to LUNX-targeting therapy
por: Jiao, Defeng, et al.
Publicado: (2021) -
Diagnostic utility of LunX mRNA in peripheral blood and pleural fluid in patients with primary non-small cell lung cancer
por: Cheng, Min, et al.
Publicado: (2008) -
Clinical and prognostic significance of detecting CEA, EGFR, LunX, c-met and EpCAM mRNA-positive cells in the peripheral blood, tumor-draining blood and bone marrow of non-small cell lung cancer patients
por: Rehulkova, Alona, et al.
Publicado: (2023) -
mRNA expression of CK19, EGFR and LUNX in patients with lung cancer micrometastasis
por: ZHANG, XIANSEN, et al.
Publicado: (2014) -
Lung specific X protein as a novel therapeutic target for lung cancer
por: Zheng, Xiaohu, et al.
Publicado: (2015)